Meeting Objectives

  • Evaluate recent clinical trial data focused on the safety and efficacy of novel therapeutic agents and combination strategies that target the tumor microenvironment in hematologic malignancies
  • Describe the impact of large-scale immune profiling efforts on the development of novel therapeutic targets
  • Explore how emerging pathways and strategies targeting the immune microenvironment are used to inform and optimize precision medicine
  • Gain insights on the role of the tumor microenvironment in solid tumors and evaluate appropriate agents that promote tumor regression
  • Foster collaboration between academic and industry researchers to evaluate novel therapeutic approaches in hematologic malignancies

Agenda is subject to change

Thursday, September 22, 2022

Duration
Topic
3:00 PM – 3:05 PM
Welcome and Introductions
3:05 PM – 3:20 PM

Presentation: Translational Workshop on Hematologic Malignancies – Lessons Learned Over the Last 10 Years
Kieron Dunleavy, MD (Georgetown University, Washington, DC)

3:20 PM – 3:50 PM
Keynote: Impact of the Microenvironment on CAR T-cells
3:50 PM – 4:05 PM

Presentation: The Role of the Microenvironment in Tumor Progression and Treatment Outcomes
Kenneth Anderson, MD (Dana-Farber Cancer Institute, Boston, MA)

4:05 PM – 4:25 PM

Breakout Session: Large-Scale Immune Profiling in Hematologic Malignancies

  • Microenvironment and Epigenetic Regulation in Lymphoma
  • Industry Perspectives
4:25 PM – 5:10 PM
Summary of Breakouts/Large Group Discussion
5:10 PM – 5:25 PM
Immune Microenvironment in Solid Tumors
5:25 PM – 5:40 PM
Panel Discussion and Q&A
5:40 PM – 5:45 PM
Wrap Up and Adjourn
7:00 PM – 10:00 PM
Welcome Dinner

Friday, September 23, 2022

Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Emerging Concepts in Immune Regulation and Targeting in Lymphoma
9:15 AM – 9:35 AM

Breakout Session: Recent Advances in Characterizing the Microenvironment in Lymphoma

  • Treatment Options for Patients with Richter’s Transformation
  • Review of Current Clinical Trial Data of CAR T, BTKi, and Bispecifics
  • Sequencing Immunotherapy and Novel Combination Strategies
  • Industry Perspectives
9:35 AM – 10:20 AM
Summary of Breakouts/Large Group Discussion
10:20 AM – 10:40 AM
DEBATE Should There Be a Personalized Approach to Target the Tumor Microenvironment?
10:40 AM – 10:55 AM
Coffee Break
10:55 AM – 11:10 AM
Presentation: Novel Therapeutic Strategies That Utilize the Microenvironment to Improve Outcomes in Leukemia
11:10 AM – 11:30 AM

Breakout Session: Current Advances Targeting the Microenvironment in

  • BTK Inhibitors in CLL
  • Role of the Microenvironment in Resistance to Therapy in AML
  • Advances in the Understanding of the Microenvironment in ALL
  • Industry Perspectives
11:30AM – 12:15 PM
Summary of Breakouts/Large Group Discussion
12:15 PM – 12:30 PM
Presentation: New Approaches for CAR T-cell Therapy in Hematologic Malignancies
Jennifer Brudno, MD (National Cancer Institute, Bethesda, MD)
12:30 PM – 1:30 PM
Lunch
1:30 PM – 1:45 PM
Presentation: Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine
Larry Boise, PhD (Emory University, Atlanta, GA)
1:45 PM – 2:05 PM

Breakout Session: Unifying Immune Therapy with Precision Medicine

  • Incorporating ctDNA into Clinical Practice
  • Interplay of Genomics with the Tumor Microenvironment
  • Industry Perspectives
2:05 PM – 2:50 PM
Summary of Breakouts/Large Group Discussion
2:50 PM – 3:00 PM
Coffee Break
3:00 PM – 3:15 PM
Industry Presentation
3:15 PM – 3:30 PM
FDA Presentation
3:30 PM – 4:00 PM
Panel Discussion and Q&A
4:00 PM – 5:00 PM
Poster Display and Discussion Session
7:00 PM – 10:00 PM
Dinner

Saturday, September 24, 2022

Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Insights into the Immune Microenvironment in Multiple Myeloma Madhav Dhodapkar, MBBS (Emory University, Atlanta, GA)
9:15 AM – 9:35 AM

Breakout Session: Targeting the Tumor Microenvironment in Multiple Myeloma

  • Impact of the Immune Microenvironment on CAR T Treatment, Proteasome Inhibitors, Anti-CD38 Monoclonal Antibodies, ADCs, CELMoDs, and IMiDs
  • Sequencing Immunotherapy and Novel Combination Strategies Industry Perspectives
9:35 PM – 10:20 AM
Summary of Breakouts/Large Group Discussion
10:20 AM – 10:50 AM

Keynote:Immune Microenvironment/Cell medicine
Helen Heslop, MD, DSc (Baylor College of Medicine, Houston, TX)

10:50 AM – 11:50 AM

Working Session

11:50 AM – 12:00 PM

Closing Remarks, Action Items for 2023, and Adjourn
Sagar Lonial, MD (Emory University, Atlanta, GA)